Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
ESMO Open|September 18, 2025
From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug developmentS Champiat, K Ouali, A Laparra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2013
Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinomaN Pécuchet, F Bigot, J Gachet, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2014
Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institutionJ Raphael, G Le Teuff, A Hollebecque, et al.
Cancer Chemotherapy and Pharmacology|August 28, 2022
A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumorsC Massard, P A Cassier, A Azaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2011
Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitorsT Bessede, C Massard, B Albouy, et al.
Prostate Cancer and Prostatic Diseases|October 15, 2014
Who dies from prostate cancer?A Patrikidou, Y Loriot, J-C Eymard, et al.
Bulletin Du Cancer|December 22, 2009
[New drugs in metastatic castration-resistant prostate cancer]L Albiges, Y Loriot, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2008
The postchemotherapy PSA surge syndromeR Thuret, C Massard, M Gross-Goupil, et al.
BMC Cancer|March 1, 2016
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancerC R Lindsay, S Le Moulec, F Billiot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapyR de Crevoisier, K Slimane, T Messai, et al.
Pageof 9